FN2 Earnings Intelligence
TG Therapeutics, Inc. cash flow
TG Therapeutics, Inc. (TGTX) Cash Flow (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $298.9 | $102.3 | $92.9 | $179.9 | $79.1 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $6.7 | $2.8 | $233.7 | $329 | $616.3 | $993.7 | $1,344.3 |
| % Growth | 4,300.7% | -58.4% | 8,290.0% | 40.8% | 87.3% | 61.2% | 35.3% |
| Gross Profit | - | - | $219.5 | $290.5 | $515.6 | - | - |
| % Margin | - | - | 94.0% | 88.3% | 83.7% | - | - |
| EBITDA | -$344.5 | -$192.5 | $20.8 | $42 | $123.4 | - | - |
| % Margin | -5,150.1% | -6,913.3% | 8.9% | 12.8% | 20.0% | - | - |
| Net Income | -$348.1 | -$198.3 | $12.7 | $23.4 | $447.2 | - | - |
| % Margin | -5,204.1% | -7,121.5% | 5.4% | 7.1% | 72.6% | - | - |
| Diluted EPS | - | -$1.46 | $0.09 | $0.15 | $2.77 | $1.03 | $2.77 |
| % Growth | - | - | 106.2% | 66.7% | 1,746.7% | -62.7% | 168.1% |
| Operating Cash Flow | -$295.6 | -$176.2 | -$31.4 | -$40.5 | -$24.8 | - | - |
| CapEx | $0.4 | $0 | $0 | $0 | $0.2 | - | - |
| Free Cash Flow | -$296 | -$176.2 | -$31.4 | -$40.6 | -$25 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $6.7 | $2.8 | $233.7 | $329 | $616.3 | $993.7 | $1,344.3 |
| Gross Profit | - | - | $219.5 | $290.5 | $515.6 | - | - |
| EBITDA | -$344.5 | -$192.5 | $20.8 | $42 | $123.4 | - | - |
| Net Income | -$348.1 | -$198.3 | $12.7 | $23.4 | $447.2 | - | - |
| Diluted EPS | - | -$1.46 | $0.09 | $0.15 | $2.77 | $1.03 | $2.77 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $298.9 | $102.3 | $92.9 | $179.9 | $79.1 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $66.8 | $71.1 | $100.1 | $244.4 | $245.6 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$295.6 | -$176.2 | -$31.4 | -$40.5 | -$24.8 |
| Capital Expenditure | $0.4 | $0 | $0 | $0 | $0.2 |
| Free Cash Flow | -$296 | -$176.2 | -$31.4 | -$40.6 | -$25 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 4,300.7% | -58.4% | 8,290.0% | 40.8% | 87.3% |
| Gross Margin | - | - | 94.0% | 88.3% | 83.7% |
| EBITDA Margin | -5,150.1% | -6,913.3% | 8.9% | 12.8% | 20.0% |
| Net Margin | -5,204.1% | -7,121.5% | 5.4% | 7.1% | 72.6% |
| FCF Margin | -4,425.7% | -6,326.2% | -13.4% | -12.3% | -4.1% |
| Diluted EPS Growth | - | - | 106.2% | 66.7% | 1,746.7% |
Get the TGTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.